Study: Thoratec's HeartMate II outperforms older cardiac pump

11/17/2009 | Wall Street Journal, The

Researchers found that Thoratec's HeartMate II, a left-ventricular assist device, was more effective than the company's older device in improving two-year survival and quality of life of severe heart-failure patients who are not fit to undergo a heart transplant or are awaiting a donor. The company is waiting for the FDA to approve the device as a long-term treatment.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY